Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 10th ed. Philadelphia: Elsevier; 2021. pp. 1222–5.
Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al. Fitzpatrick’s dermatology in general medicine. 9th ed. New York: McGraw-Hill; 2019. pp. 393–9.
Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications.Allergy Asthma Proc. 2019;40:84–92. [DOI] [PubMed] [PMC]
Kuo WT, Odenwald MA, Turner JR, Zuo L. Tight junction proteins occludin and ZO-1 as regulators of epithelial proliferation and survival.Ann N Y Acad Sci. 2022;1514:21–33. [DOI] [PubMed] [PMC]
Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis.Int J Mol Sci. 2020;21:2867. [DOI] [PubMed] [PMC]
Sugiyama S, Sasaki T, Tanaka H, Yan H, Ikegami T, Kanki H, et al. The tight junction protein occludin modulates blood-brain barrier integrity and neurological function after ischemic stroke in mice.Sci Rep. 2023;13:2892. [DOI] [PubMed] [PMC]
Yuan S, Li W, Hou C, Kang H, Ma Q, Ji X, et al. Serum Occludin Level Combined With NIHSS Score Predicts Hemorrhage Transformation in Ischemic Stroke Patients With Reperfusion.Front Cell Neurosci. 2021;15:714171. [DOI] [PubMed] [PMC]
Beck LA, Cork MJ, Amagai M, De Benedetto A, Kabashima K, Hamilton JD, et al. Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis.JID Innov. 2022;2:100131. [DOI] [PubMed] [PMC]
Pummi K, Malminen M, Aho H, Karvonen SL, Peltonen J, Peltonen S. Epidermal tight junctions: ZO-1 and occludin are expressed in mature, developing, and affected skin and in vitro differentiating keratinocytes.J Invest Dermatol. 2001;117:1050–8. [DOI] [PubMed]
Kirschner N, Poetzl C, von den Driesch P, Wladykowski E, Moll I, Behne MJ, et al. Alteration of tight junction proteins is an early event in psoriasis: putative involvement of proinflammatory cytokines.Am J Pathol. 2009;175:1095–106. [DOI] [PubMed] [PMC]
Peltonen S, Riehokainen J, Pummi K, Peltonen J. Tight junction components occludin, ZO-1, and claudin-1, -4 and -5 in active and healing psoriasis.Br J Dermatol. 2007;156:466–72. [DOI] [PubMed]
Yoshida Y, Morita K, Mizoguchi A, Ide C, Miyachi Y. Altered expression of occludin and tight junction formation in psoriasis.Arch Dermatol Res. 2001;293:239–44. [DOI] [PubMed]
Saito AC, Higashi T, Fukazawa Y, Otani T, Tauchi M, Higashi AY, et al. Occludin and tricellulin facilitate formation of anastomosing tight-junction strand network to improve barrier function.Mol Biol Cell. 2021;32:722–38. [DOI] [PubMed] [PMC]
Rawat M, Nighot M, Al-Sadi R, Gupta Y, Viszwapriya D, Yochum G, et al. IL1B Increases Intestinal Tight Junction Permeability by Up-regulation of MIR200C-3p, Which Degrades Occludin mRNA.Gastroenterology. 2020;159:1375–89. [DOI] [PubMed] [PMC]
